First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

NCT05737628 · clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
17
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Byondis B.V.